Anqing Chico Pharmaceutical Co., Ltd. (ANQING CHICO) is a high-tech enterprise specializing in THE SERVICE OF APIS mAh/CDMO and the production of high-end pharmaceutical intermediates invested and built by Nanjing Qike Pharmaceutical Co., Ltd. Since its inception, the company has always focused on the research and development and production of small molecules targeted anti-tumor, anti-diabetic, anti-cardiovascular and cerebrovascular, anti-viral series and other pharmaceutical raw materials and intermediates. The company is located in the provincial chemical park - Anqing High-tech Industrial Development Zone, covers an area of 20, 000 square meters, construction area of 11, 000 square meters, built 2 three-story Class A factory buildings, a total of 6 workshops, of which 2 workshops for high-end pharmaceutical intermediates production workshop, 4 workshops for API GMP production workshops, used to provide mAh services. R & D center is located in Nanjing Qixia District Xianlin University Town Weidi Road No. 9 Jiangsu Life Science and Technology Innovation Park, construction area of 1800 square meters, has an experienced, energetic R & D team, and equipped with advanced organic synthesis and analysis testing instruments and equipment, in accordance with the requirements of the network version of the data audit tracking system, the management system passed the ISO9001 quality certification, in line with the requirements of API registration and declaration regulations. Driven by R&D, the company has continuously increased R&D investment, and has successfully developed: Small molecule targeted anti-tumor products: Gefitinib, erlotinib, pezopanib, lapatinib, afatinib, levatinib and other 21 projects; Diabetes products: Siglittine, lifiglitine, alogliptin, dapagliflozin, cangliflozin and other 16 items; Cardiovascular and cerebrovascular products: Apixaban, rivaroxaban, betroxaban, dofelitic and other 7 projects; Antiviral products: Tenofovir, and other 4 items. With the expiration of the patent generic drug listed, some projects have been successfully commercialized mass production, and every 1-2 years there will be new projects approved for listing, will inject the company with sustainable development momentum. Through the successful development of tenib, columnin, liejing, shaban and other series of products, the company has established close cooperative relations with more than 30 of the top 100 enterprises in the domestic pharmaceutical industry to help the research and development of domestic generic drugs. In addition, it has also vigorously expanded overseas markets, and has also established cooperative relations with some of the top ten companies in India, and passed their supplier qualification audits. The company adheres to the innovation development strategy and pays attention to the creation of enterprise scientific and technological innovation capabilities. In 2018, he participated in the 7th China Innovation and Entrepreneurship Competition held by the Ministry of Science and Technology and won the "Excellent Enterprise Award" in the national finals. In 2019, the company's core team was recognized as "Provincial High-level Scientific and Technological Talent Team" by the Science and Technology Department of Anhui Province. The company always regards quality as life, and has established a strict quality assurance system with reference to GMP requirements. In accordance with the requirements of relevant national EHS laws and regulations, we have established a sound EHS management system and strive to create a safe, healthy and clean working environment for employees to achieve the sustainable development of the company. The company has always been adhering to the "service for respect, integrity.